Ironwood Pharmaceuticals is trading 11% up at $4.14, extending a multi-day rebound after recent volatility and losses earlier this week.
- The upward move appears to be driven by technical momentum and renewed risk appetite, standing out as a notable outperformer against broader biotech sector weakness.
- There is no fresh company-specific news, earnings, or major regulatory filings reported for July 31, 2026, to account for the price action.